Acadian Asset Management
CNTX icon

Acadian Asset Management’s Context Therapeutics CNTX Stock Holding History

Acadian Asset Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,668
Closed -$17K – 1648
2024
Q4 		$17K Buy
+16,668
New +$28.8K ﹤0.01% 1550

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management's CNTX Position: Q1 2025 in Review

Acadian Asset Management sold out of Context Therapeutics (CNTX) in Q1 2025, closing a stake of 16,668 shares — an estimated $17K sold.

Acadian Asset Management first reported a position in CNTX in Q4 2024 and held it in 1 quarter. The position peaked at $17K in Q4 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q1 2025.

  • Acadian Asset Management reported no remaining Context Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Acadian Asset Management sold 16,668 Context Therapeutics shares in Q1 2025, an estimated $17K.
  • Acadian Asset Management first reported a position in Context Therapeutics in Q4 2024 and held it in 1 quarter.
  • Acadian Asset Management's Context Therapeutics position peaked at $17K in Q4 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2025.

Based on Acadian Asset Management's 13F filing for Q1 2025, filed 21 May 2025.